Prediction of drugs having opposite effects on disease genes in a directed network

BMC Systems Biology

Volumn 10, Issue 1, 2016, Pages

  Yu, Hasun ^a,b   Choo, Sungji ^a,b   Park, Junseok ^a,b   Jung, Jinmyung ^a,b   Kang, Yeeok ^a,b   Lee, Doheon ^a,b  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b BioProcess Engineering Research Center   (South Korea)

Author keywords

Directed network; Drug repositioning; Network biology

Indexed keywords

ALGORITHM; BIOLOGY; DRUG INTERACTION; DRUG REPOSITIONING; DRUG THERAPY; HUMAN; PROCEDURES;

ALGORITHMS; COMPUTATIONAL BIOLOGY; DRUG INTERACTIONS; DRUG REPOSITIONING; DRUG THERAPY; HUMANS;

EID: 84953871494     PISSN: None     EISSN: 17520509     Source Type: Journal    
DOI: 10.1186/s12918-015-0243-2     Document Type: Article

References (39)

1. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22(2):151-85.
2. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32(1):40-51.
3. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3(8):673-83.
4. Dudley JT, Sirota M, Shenoy M, Pai RK, Roedder S, Chiang AP. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med. 2011;3(96):96ra76.
5. Hu G, Agarwal P. Human disease-drug network based on genomic expression profiles. PLoS One. 2009;4(8):e6536.
6. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313(5795):1929-35.
7. Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, Sweet-Cordero A. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med. 2011;3(96):96ra77.
8. Cheng F, Liu C, Jiang J, Lu W, Li W, Liu G, et al. Prediction of drug-target interactions and drug repositioning via network-based inference. PLoS Comput Biol. 2012;8(5):e1002503.
9. Emig D, Ivliev A, Pustovalova O, Lancashire L, Bureeva S, Nikolsky Y, et al. Drug target prediction and repositioning using an integrated network-based approach. PLoS One. 2013;8(4):e60618.
10. Wang W, Yang S, Zhang X, Li J. Drug repositioning by integrating target information through a heterogeneous network model. Bioinformatics. 2014;30(20):2923-30.
11. Wang Y, Zeng J. Predicting drug-target interactions using restricted Boltzmann machines. Bioinformatics. 2013;29(13):i126-i34.
12. Qabaja A, Alshalalfa M, Alanazi E, Alhajj R. Prediction of novel drug indications using network driven biological data prioritization and integration. J Cheminformatics. 2014;6(1):1.
13. Fukuoka Y, Takei D, Ogawa H. A two-step drug repositioning method based on a protein-protein interaction network of genes shared by two diseases and the similarity of drugs. Bioinformation. 2013;9(2):89-93. doi: 10.6026/97320630009089.
14. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27-30.
15. Zhang JD, Wiemann S. KEGGgraph: a graph approach to KEGG PATHWAY in R and bioconductor. Bioinformatics. 2009;25(11):1470-1.
16. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006;34 suppl 1:D668-D72.
17. Davis AP, Murphy CG, Saraceni-Richards CA, Rosenstein MC, Wiegers TC, Mattingly CJ. Comparative Toxicogenomics Database: a knowledgebase and discovery tool for chemical-gene-disease networks. Nucleic Acids Res. 2009;37 suppl 1:D786-D92.
18. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207-10.
19. Lowe HJ, Barnett GO. Understanding and using the medical subject headings (MeSH) vocabulary to perform literature searches. Jama. 1994;271(14):1103-8.
20. Smyth GK. Limma: linear models for microarray data. Bioinformatics and computational biology solutions using R and Bioconductor. New York: Springer; 2005. p. 397-420.
21. Jeanmougin M, De Reynies A, Marisa L, Paccard C, Nuel G, Guedj M. Should we abandon the t-test in the analysis of gene expression microarray data: a comparison of variance modeling strategies. PLoS One. 2010;5(9):e12336.
22. Stobbe MD, Swertz MA, Thiele I, Rengaw T, Van Kampen AH, Moerland PD. Consensus and conflict cards for metabolic pathway databases. BMC Syst Biol. 2013;7(1):50.
23. Yoon S, Jung J, Yu H, Kwon M, Choo S, Park K et al. Context-based resolution of semantic conflicts in biological pathways. BMC medical informatics and decision making. 2015;15 Suppl 1:S3. doi: 10.1186/1472-6947-15-S1-S3.
24. Ajibade AA, Wang HY, Wang R-F. Cell type-specific function of TAK1 in innate immune signaling. Trends Immunol. 2013;34(7):307-16.
25. Scheiber J, Chen B, Milik M, Sukuru SCK, Bender A, Mikhailov D, et al. Gaining insight into off-target mediated effects of drug candidates with a comprehensive systems chemical biology analysis. J Chem Inf Model. 2009;49(2):308-17.
26. Yildirim MA, Goh K-I, Cusick ME, Barabási A-L, Vidal M. Drug-target network. Nat Biotechnol. 2007;25(10):1119-26.
27. Domercq M, Matute C. Neuroprotection by tetracyclines. Trends Pharmacol Sci. 2004;25(12):609-12. doi: 10.1016/j.tips.2004.10.001.
28. Rajoria S, Suriano R, George A, Shanmugam A, Schantz SP, Geliebter J, et al. Estrogen induced metastatic modulators MMP-2 and MMP-9 are targets of 3,3'-diindolylmethane in thyroid cancer. PLoS One. 2011;6(1):e15879. doi: 10.1371/journal.pone.0015879.
29. Prichard CN, Kim S, Yazici YD, Doan DD, Jasser SA, Mandal M, et al. Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma. Laryngoscope. 2007;117(4):674-9. doi: 10.1097/MLG.0b013e318031055e.
30. Kim S, Prichard CN, Younes MN, Yazici YD, Jasser SA, Bekele BN, et al. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin Cancer Res. 2006;12(2):600-7. doi: 10.1158/1078-0432.CCR-05-1325.
31. Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ, et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid. 2008;18(3):317-23. doi: 10.1089/thy.2007.0120.
32. Frasca F, Vella V, Nicolosi ML, Messina RL, Giani F, Lotta S, et al. Thyroid cancer cell resistance to gefitinib depends on the constitutive oncogenic activation of the ERK pathway. J Clin Endocrinol Metab. 2013;98(6):2502-12. doi: 10.1210/jc.2012-3623.
33. Kurebayashi J, Okubo S, Yamamoto Y, Ikeda M, Tanaka K, Otsuki T, et al. Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells. Cancer Chemother Pharmacol. 2006;58(4):460-70. doi: 10.1007/s00280-006-0185-x.
34. Hogan T, Jing Jie Y, Williams HJ, Altaha R, Xiaobing L, Qi H. Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib. J Oncol Pharm Pract. 2009;15(2):111-7. doi: 10.1177/1078155208101212.
35. Masago K, Miura M, Toyama Y, Togashi Y, Mishima M. Good clinical response to erlotinib in a patient with anaplastic thyroid carcinoma harboring an epidermal growth factor somatic mutation, L858R, in exon 21. J Clin Oncol. 2011;29(16):e465-7. doi: 10.1200/JCO.2010.34.0216.
36. Landriscina M, Maddalena F, Fabiano A, Piscazzi A, La Macchia O, Cignarelli M. Erlotinib enhances the proapoptotic activity of cytotoxic agents and synergizes with paclitaxel in poorly-differentiated thyroid carcinoma cells. Anticancer Res. 2010;30(2):473-80.
37. Maglott D, Ostell J, Pruitt KD, Tatusova T. Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res. 2005;33 suppl 1:D54-D8.
38. Li S, Zhang B, Zhang N. Network target for screening synergistic drug combinations with application to traditional Chinese medicine. BMC Syst Biol. 2011;5 Suppl 1:S10. doi: 10.1186/1752-0509-5-S1-S10.
39. Zou J, Ji P, Zhao YL, Li LL, Wei YQ, Chen YZ, et al. Neighbor communities in drug combination networks characterize synergistic effect. Mol BioSyst. 2012;8(12):3185-96. doi: 10.1039/c2mb25267h.